- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 28.11.25 | IASO Bio gains Hong Kong approval for Fucaso application | ||
| 27.11.25 | Valneva trims R&D footprint by shutting French facility | ||
| 27.11.25 | SK bolsters oncology pipeline in radiopharmaceutical licensing deal | ||
| 27.11.25 | BeOne's sonrotoclax gains priority FDA review for mantle cell lymphoma | ||
| 27.11.25 | Corstasis Therapeutics partners CVL for Enbumyst integration | ||
| 26.11.25 | Reeves' Autumn Budget targets community health centres and NHS tech outlay | ||
| 26.11.25 | Dupixent gains chronic spontaneous urticaria indication in Europe | ||
| 26.11.25 | Questions on how new IRA drug prices will affect MFN agreements | ||
| 26.11.25 | Novartis axes 550 jobs at Swiss manufacturing site | ||
| 26.11.25 | UNICEF and Gavi to widen affordable malaria vaccine access | ||
| 26.11.25 | FDA grants accelerated approval for Otsuka's IgAN therapy | ||
| 25.11.25 | Gilead snaps up Sprint's TREX1 immunotherapy programme for $400m | ||
| 25.11.25 | UK-developed leukaemia cell therapy to be offered on NHS | ||
| 25.11.25 | Made Scientific and Cellergy partner to advance CLG-001 | ||
| 25.11.25 | Novartis secures approval from FDA for Itvisma to treat SMA | ||
| 24.11.25 | GLP-1RA Alzheimer's hopes dashed after Novo Nordisk's semaglutide miss | ||
| 24.11.25 | Eli Lilly flies the pharma flag in tech-heavy $1tn market cap club | ||
| 24.11.25 | Navigating the FDA's import operations for pharmaceuticals and biologics | ||
| 24.11.25 | Investors bet on newer technology and indications for CGTs | ||
| 24.11.25 | AstraZeneca to expand biomanufacturing in Maryland, US | ||
| 24.11.25 | Vaximm and BCME link on oral cancer immunotherapy platform | ||
| 21.11.25 | "Reckless and harmful": experts weigh in on CDC's autism-vaccine link stance | ||
| 21.11.25 | Early planning, outsourcing and digitalisation to break down CGT CMC barriers | ||
| 21.11.25 | Aspen closes $115m in Series C to advance Parkinson's cell therapy | ||
| 21.11.25 | Alvotech and Advanz announce EC approval for Gobivaz biosimilar |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .